Back
Admissibility of medicine for claim
Share
02 Apr, 2022
by R Lalittha
Ujvira (T-DM1) or trastusumab-emtansine to treat Her2 + CA Breast in adjuvant treatment is prescribed as protocol by treating doctor. Insurer rejects claim on grounds that it is "mono clonal antibody" and hence exceeded sublimits. whereas , its a conjugate biosimilar of the two medicines mentioned above. Can you please clarify?
thanks
0
Post
0
0 Comments
Reply
09 Apr, 2022
R Lalittha
Sir it's very kind of you to reply to the query. Not sure whether this medicine is to be treated as monoclonal antibody are a chemo drug.
Thanks for your valuable time
Regards
0
0 Comments Reply
Dear Lalittha,
Monoconol Anitibody is classified under Modern Treatment. Many plans have a limit defined for such treatments. Kindly cross check your plan for sub limits towards modern treatment. Currently it seems the limit has been reached and hence the claim is not paid.
Regards
Rohit Dhingra